Further implications on the global real-world vaccine effectiveness against SARS-CoV-2

Abstract

We have recently reported a global review of vaccine effec-tiveness (VE) data evaluating almost 80 real-world studies. Atthe time of data extraction (10 February 2022), the vast majorityof studies were limited to two-dose primary vaccination sche-dules and were predominantly conducted before the emergenceof the Omicron variants. To address gaps in the data relating toVE against the Omicron variant, and significantly after the use ofbooster doses, we have already begun to evaluate a more recentdata cut and hope to be able to share that analysis soon...